1,1,1-trifluoro-3-nitro-2-pentanol | 127074-03-7

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 英文名称: 1,1,1-trifluoro-3-nitro-2-pentanol
• 英文别名: 1,1,1-trifluoro-3-nitropentan-2-ol
• CAS: 127074-03-7
• 化学式: C₅H₈F₃NO₃
• 分子量: 187.119
• InChiKey: UIEPDCACBJEBNK-UHFFFAOYSA-N

物化性质

• 沸点：
  57-58 °C(Press: 4 Torr)
• 密度：
  1.351±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  66
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1,1,1-trifluoro-3-nitro-2-pentanol 在 硫酸 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 四氢呋喃 为溶剂， 反应 12.0h， 生成 tert-butyl 4-ethyl-3-(trifluoromethyl)-1H-pyrrole-2-carboxylate
  参考文献：
  名称：

  三氟甲基化吡咯和卟啉的简便合成

  摘要：

  4-烷基-3-三氟甲基-2-吡咯甲酸酯（2）可通过三氟甲基化β-硝基乙酸酯（1）与异氰乙酸乙酯反应方便地制备。吡咯通过 2-（羟甲基）吡咯的四聚作用转化为相应的卟啉。

  DOI：

  10.1246/bcsj.62.3386
• 作为产物：
  描述：

  硝基丙烷 、 1-乙氧基-2,2,2-三氟乙醇 在 盐酸 、 potassium carbonate 作用下， 生成 1,1,1-trifluoro-3-nitro-2-pentanol
  参考文献：
  名称：

  Heterocyclic amides

  摘要：

  本发明涉及某些新颖的杂环酰胺，它们是式I所示的1-吡啶乙酰胺化合物，这些化合物是人类白细胞弹性蛋白酶（HLE）的抑制剂，也被称为人类中性粒细胞弹性蛋白酶（HNE），使它们在需要这种抑制作用时非常有用，例如用作药理学、诊断和相关研究工具以及治疗哺乳动物中HLE相关疾病。该发明还包括在合成这些杂环酰胺过程中有用的中间体，制备这些杂环酰胺的方法，含有这些杂环酰胺的药物组合物以及它们的使用方法。

  公开号：

  US05521179A1

文献信息

• Heterocyclic amides
  申请人：Zeneca Limited

  公开号：US05521179A1

  公开（公告）日：1996-05-28

  The present invention relates to certain novel heterocyclic amides which are 1-pyridylacetamide compounds of formula I, set out herein, which are inhibitors of human leukocyte elastase (HLE), also known as human neutrophil elastase (HNE), making them useful whenever such inhibition is desired, such as for research tools in pharmacological, diagnostic and related studies and in the treatment of diseases in mammals in which HLE is implicated. The invention also includes intermediates useful in the synthesis of these heterocyclic amides, processes for preparing the heterocyclic amides, pharmaceutical compositions containing such heterocyclic amides and methods for their use.

  本发明涉及某些新颖的杂环酰胺，它们是式I所示的1-吡啶乙酰胺化合物，这些化合物是人类白细胞弹性蛋白酶（HLE）的抑制剂，也被称为人类中性粒细胞弹性蛋白酶（HNE），使它们在需要这种抑制作用时非常有用，例如用作药理学、诊断和相关研究工具以及治疗哺乳动物中HLE相关疾病。该发明还包括在合成这些杂环酰胺过程中有用的中间体，制备这些杂环酰胺的方法，含有这些杂环酰胺的药物组合物以及它们的使用方法。
• COMPOUNDS
  申请人：SHELDRAKE Peter William

  公开号：US20100093769A1

  公开（公告）日：2010-04-15

  The present invention relates to compounds of formula (I) wherein: R 1 and R 2 are each independently H, alkyl or haloalkyl; R 3 and R 4 are each independently H, alkyl, haloalkyl or aryl; R 5 is alkyl or cycloalkyl or cycloalkyl-alkyl, each of which may be optionally substituted with one or more OH groups; R 6 is selected from cyclopropylamino, cyclopropylmethylamino, cyclobutylamino, cyclobutylmethylamino and where one of X, Y and Z is N and the remainder are CR 9 ; R 7 , R 8 and each R 9 are independently H, alkyl or haloalkyl, wherein at least one of R 7 , R 8 and each R 9 is other than H. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula (I), and the use of said compounds in treating proliferative disorders, viral disorders, stroke, alopecia, CNS disorders, neurodegenerative disorders, or diabetes.

  本发明涉及式(I)化合物，其中： R1和R2各自独立地为H、烷基或卤代烷基； R3和R4各自独立地为H、烷基、卤代烷基或芳基； R5为烷基或环烷基或环烷基烷基，每个基团可以选择性地被一个或多个OH基团取代； R6选自环丙基氨基、环丙基甲基氨基、环丁基氨基、环丁基甲基氨基和其中的一个，其中X、Y和Z中的一个为N，其余为CR9； R7、R8和每个R9各自独立地为H、烷基或卤代烷基，其中至少一个R7、R8和每个R9不是H。 本发明的另一个方面涉及包含式(I)化合物的药物组合物，以及使用该化合物治疗增殖性疾病、病毒性疾病、中风、脱发、中枢神经系统疾病、神经退行性疾病或糖尿病的方法。
• Trisubstituted purine derivatives
  申请人：Sheldrake Peter William

  公开号：US08592581B2

  公开（公告）日：2013-11-26

  The present invention relates to compounds of formula (I) wherein: R1 and R2 are each independently H, alkyl or haloalkyl; R3 and R4 are each independently H, alkyl, haloalkyl or aryl; R5 is alkyl or cycloalkyl or cycloalkyl-alkyl, each of which may be optionally substituted with one or more OH groups; R6 is selected from cyclopropylamino, cyclopropylmethylamino, cyclobutylamino, cyclobutylmethylamino and where one of X, Y and Z is N and the remainder are CR9; R7, R8 and each R9 are independently H, alkyl or haloalkyl, wherein at least one of R7, R8 and each R9 is other than H. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula (I), and the use of said compounds in treating proliferative disorders, viral disorders, stroke, alopecia, CNS disorders, neurodegenerative disorders, or diabetes.

  本发明涉及式（I）的化合物，其中： R1和R2各自独立地为H、烷基或卤代烷基； R3和R4各自独立地为H、烷基、卤代烷基或芳基； R5为烷基或环烷基或环烷基烷基，其中每个基团可以选择地被一个或多个OH基团取代； R6选择自环丙氨基、环丙甲基氨基、环丁氨基、环丁甲基氨基和其中X、Y和Z中的一个为N，其余为CR9； R7、R8和每个R9各自独立地为H、烷基或卤代烷基，其中至少一个R7、R8和每个R9不是H。 本发明的另一个方面涉及包含式（I）的化合物的制药组合物，以及使用该化合物治疗增殖性疾病、病毒性疾病、中风、脱发、中枢神经系统疾病、神经退行性疾病或糖尿病的用途。
• Peptidomimetic Inhibitors of the Human Cytomegalovirus Protease
  作者：William Ogilvie、Murray Bailey、Marc-André Poupart、Abraham、Amit Bhavsar、Pierre Bonneau、Josée Bordeleau、Yves Bousquet、Catherine Chabot、Jean-Simon Duceppe、Gulrez Fazal、Sylvie Goulet、Chantal Grand-Maître、Ingrid Guse、Ted Halmos、Pierre Lavallée、Michael Leach、Eric Malenfant、Jeff O'Meara、Raymond Plante、Céline Plouffe、Martin Poirier、François Soucy、Christiane Yoakim、Robert Déziel

  DOI：10.1021/jm970104t

  日期：1997.12.1

  The development of peptidomimetic inhibitors of the human cytomegalovirus (HCMV) :protease showing sub-micromolar potency in an enzymatic assay is described. Selective substitution of the amino acid residues of these inhibitors led to the identification of tripeptide inhibitors showing improvements in inhibitor potency cf 27-fold relative to inhibitor 39 based upon the natural tetrapeptide sequence. Small side chains at P-1 were well tolerated by this enzyme, a fact consistent with previous observations. The S-2 binding pocket of HCMV protease was very permissive, tolerating lipophilic and basic residues. The substitutions tried at P-3 indicated that a small increase in inhibitor potency could be realized by the substitution of a tert-leucine residue for valine. Substitutions of the N-terminal capping group did not significantly affect inhibitor potency. Pentafluoroethyl ketones, alpha,alpha-difluoro-beta-keto amides, phosphonates and a-keto amides were all effective substitutions for the activated carbonyl component and gave inhibitors which were selective for HCMV protease. A slight increase in potency was observed by lengthening the P-1' residue of the alpha-keto amide series of inhibitors. This position also tolerated a variety of groups making this a potential site for future modifications which could modulate the physicochemical properties of these molecules.
• WO2008/122767
  申请人：——

  公开号：——

  公开（公告）日：——